“Dr. Saphier would be a catastrophic mistake on messaging and communicating with MAHA at a time where the coalition is very fragile,” one opponent says. 

The Erlangen, Germany-based device manufacturer announced its quarterly earnings results on May 7, which included a 6.5% year-over-year decline in revenue for its diagnostics segment. 

First approved by the FDA in 2021, providers have rapidly adopted this clinical innovation, which offers greater accuracy in detecting prostate cancer.